Antisoma PLC (ASM.L) Announces Discontinuation of Development of AS1402  
8/7/2009 8:06:49 AM

Bookmark and Share

London, UK, and Cambridge, MA: Antisoma plc today announces that the phase II trial of AS1402 in breast cancer is to be discontinued. This follows a meeting of the trial’s Data Monitoring Committee (DMC) and a subsequent review of the data, which led the company to conclude that the trial would be very unlikely to give sufficiently positive efficacy findings. No safety concerns were identified. Antisoma has no plans for further studies of AS1402.